加载中
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
收盘时
US$96.79
−US$1.77 · -1.80%
盘后
US$96.77
−US$0.02 · -0.02%
10月13日 16:38 ET
盘中时间采用ET。市场数据可能有所延迟。
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
日内区间
当前US$96.79
52周区间
当前US$96.79
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
53
合理估值
情绪
65
看涨
风险
56
风险偏高
动量
37
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
日内区间
当前US$96.79
52周区间
当前US$96.79
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 6.06亿 USD | 3.64亿 USD | 3.05亿 USD | 2.45亿 USD | 1.88亿 USD |
| 销货成本 | 1.25亿 USD | 8574.2万 USD | 6557.3万 USD | 5512.6万 USD | 4415.2万 USD |
| 毛利 | 4.82亿 USD | 2.78亿 USD | 2.4亿 USD | 1.9亿 USD | 1.44亿 USD |
| 研究与开发 | 7.71亿 USD | 5.98亿 USD | 5.71亿 USD | 3.98亿 USD | 2.73亿 USD |
| 销售、一般及管理费用 | 7.01亿 USD | 4.61亿 USD | 3.45亿 USD | 2.66亿 USD | 2.34亿 USD |
| 营业费用 | 16.58亿 USD | 11.56亿 USD | 9.49亿 USD | 6.48亿 USD | 5.19亿 USD |
| 利息收入 | 6065.6万 USD | 5330.7万 USD | 4213.2万 USD | 1108.1万 USD | 17.4万 USD |
| 利息支出 | 8379.5万 USD | 8491.3万 USD | 8169.4万 USD | 2644.6万 USD | 4047.3万 USD |
| 折旧和摊销 | 1645万 USD | 1101.3万 USD | 1057.9万 USD | 1033.1万 USD | 1418.2万 USD |
| 营业利润 | −11.77亿 USD | −8.78亿 USD | −7.1亿 USD | −4.57亿 USD | −3.75亿 USD |
| 净利润 | −12.77亿 USD | −9.14亿 USD | −7.5亿 USD | −4.82亿 USD | −4.35亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$197.44
上涨空间 103.99%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2011年3月3日 | 1:10 | — | — |
股票拆分 | 2000年7月31日 | 1:4 | — | — |
已生效 2011年3月3日
1:10
已生效 2000年7月31日
1:4
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI8.4亿0.04%2.3万亿 USD0.03%US$381.32-0.07%
Vanguard Extended Market ETFVXF3.07亿0.32%954亿 USD0.05%US$232.54-0.42%
Vanguard Morningstar Small-Cap ETFVB3.04亿0.16%1853亿 USD0.03%US$288.160.00%
Vanguard Morningstar Mid-Cap ETFVO2.86亿0.13%2264亿 USD0.03%US$81.02+0.12%
Vanguard Morningstar Growth ETFVUG2.18亿0.06%3846亿 USD0.03%US$91.75+0.12%
Vanguard Morningstar Small-Cap Growth ETFVBK1.74亿0.38%447亿 USD0.05%US$338.78-0.62%
iShares Biotechnology ETFIBB1.65亿1.53%108.2亿 USD0.44%US$200.02-2.08%
iShares Russell Mid-Cap Growth ETFIWP1.19亿0.60%200.95亿 USD0.23%US$140.45-0.38%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Mid-Cap ETFVOVanguard Morningstar Growth ETFVUGVanguard Morningstar Small-Cap Growth ETFVBKiShares Biotechnology ETFIBBiShares Russell Mid-Cap Growth ETFIWPAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
